Cullinan Therapeutics, Inc. has announced the appointment of Mary Kay Fenton as its new Chief Financial Officer effective April 29. CEO Nadim Ahmed expressed confidence in Fenton’s vast experience and strategic prowess, particularly pertinent as Cullinan expands into autoimmune diseases and progresses with its oncology portfolio. Mary Kay Fenton brings three decades of experience from her previous roles, notably as Interim CEO and CFO at Talaris Therapeutics, CFO and COO at Semma Therapeutics (acquired by Vertex), and CFO of Achillion Pharmaceuticals (acquired by AstraZeneca). Her track record involves crucial contributions to growth, handling financial and operational leadership, and managing significant transactions including fundraising, strategy, collaborations, and M&A activities. Fenton’s anticipation to drive Cullinan’s diversified pipeline growth and shareholder value-promoting strategies aligns with the company’s vision of developing transformative therapeutics and pursuing first- and best-in-class programs. Cullinan Therapeutics remains committed to its mission of setting new care standards and boasts a broad portfolio targeting key disease drivers in oncology and autoimmune sectors using a range of therapeutic modalities.

Biopharmaceuticals, Healthcare,United States